Aldeyra Therapeutics faces securities lawsuit
Analysis based on 6 articles · First reported May 18, 2026 · Last updated May 29, 2026
The class action lawsuit against Aldeyra Therapeutics for alleged false and misleading statements regarding its drug candidate reproxalap is likely to negatively impact the company's stock price and investor confidence. Investors who purchased Aldeyra Therapeutics securities during the Class Period may suffer financial losses, while The Schall Law Firm stands to gain from representing these investors.
The Schall Law Firm has initiated a class action lawsuit against Aldeyra Therapeutics, alleging that the company made false and misleading statements to the market regarding its reproxalap drug candidate. The complaint states that the results of clinical trials for reproxalap suffered from inconsistencies, making the company's positive statements unreliable. Investors who purchased Aldeyra Therapeutics securities between November 3, 2023, and March 16, 2026, are encouraged to join the lawsuit before May 29, 2026. The lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated by the United States — United States Securities and Exchange Commission. The Schall Law Firm, led by Brian Schall, specializes in shareholder rights litigation and represents investors globally.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard